Compare IMNM & JPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMNM | JPC |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2020 | 2003 |
| Metric | IMNM | JPC |
|---|---|---|
| Price | $19.66 | $7.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.80 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,127.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.15 | $6.79 |
| 52 Week High | $27.65 | $8.30 |
| Indicator | IMNM | JPC |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 23.37 |
| Support Level | $19.26 | N/A |
| Resistance Level | $22.57 | $8.21 |
| Average True Range (ATR) | 1.03 | 0.11 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 1.14 | 13.73 |
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.